Vincerx Pharma, Inc. (NASDAQ:VINC - Free Report) - Equities research analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for shares of Vincerx Pharma in a research report issued to clients and investors on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings of ($0.63) per share for the year, up from their prior estimate of ($0.66). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Vincerx Pharma's current full-year earnings is ($0.99) per share.
Vincerx Pharma Stock Performance
Vincerx Pharma stock traded down $0.68 during mid-day trading on Thursday, reaching $5.92. The company's stock had a trading volume of 435,166 shares, compared to its average volume of 1,065,650. Vincerx Pharma has a 12-month low of $0.61 and a 12-month high of $9.37. The company has a market capitalization of $126.75 million, a P/E ratio of -3.22 and a beta of 1.10. The firm's fifty day moving average price is $3.97 and its two-hundred day moving average price is $1.99.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of VINC. Sage Rhino Capital LLC grew its position in shares of Vincerx Pharma by 1.0% during the 3rd quarter. Sage Rhino Capital LLC now owns 1,703,413 shares of the company's stock valued at $1,720,000 after purchasing an additional 16,476 shares in the last quarter. Affinity Asset Advisors LLC grew its position in shares of Vincerx Pharma by 21.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,374,098 shares of the company's stock valued at $5,496,000 after purchasing an additional 238,733 shares in the last quarter. Rock Springs Capital Management LP grew its position in shares of Vincerx Pharma by 0.6% during the 1st quarter. Rock Springs Capital Management LP now owns 814,194 shares of the company's stock valued at $3,257,000 after purchasing an additional 4,999 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Vincerx Pharma by 1.8% during the 1st quarter. Vanguard Group Inc. now owns 666,019 shares of the company's stock worth $2,664,000 after acquiring an additional 11,667 shares during the last quarter. Finally, Citadel Advisors LLC lifted its holdings in shares of Vincerx Pharma by 5.9% during the 2nd quarter. Citadel Advisors LLC now owns 660,522 shares of the company's stock worth $859,000 after acquiring an additional 36,595 shares during the last quarter. 44.02% of the stock is currently owned by hedge funds and other institutional investors.
About Vincerx Pharma
(
Get Free Report)
Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.
Featured Articles
Before you consider Vincerx Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vincerx Pharma wasn't on the list.
While Vincerx Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
